Reconstitution of T cell function in patients with subacute sclerosing panencephalitis treated with thymus humoral factor.
Two patients with subacute sclerosing panencephalitis (SSPE) showed impairment of cell-mediated immunity, as indicated by a low T cell number, decreased intracellular cyclic AMP levels of peripheral blood lymphocytes, negative graft-vs.-host reaction in vivo, negative skin reactions to common antigens and, in one of the patients, abnormal reactions in migration inhibition factor tests. Since some of the impaired T cell functions in one of the patients were reconstituted in vitro by the administration of thymus humoral factor (THF), a thymic hormone shown in an earlier study to regulate maturation of T lymphocytes in in vitro and in vivo animal models, a course of THF administration was given to both patients in this study. In vitro and in vivo assays, which reflect T cell competence, were performed before and after a daily schedule of THF administration that lasted for 10 days in one patient and 21 days in the other. The results of this preliminary trial suggested that THF was capable of reconstituting the impaired T cell functions in both patients after a short term of treatment. These preliminary results should encourage additional long-term therapeutic trials with THF in SSPE patients with impaired cell-mediated immunity.
D000818:Animals; D002648:Child; D000242:Cyclic AMP / Q000097:blood; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D051381:Rats; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013951:Thymus Hormones / Q000276:immunology / Q000627:therapeutic use*
D013951:Thymus Hormones; D000242:Cyclic AMP